|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:DEF_Biologics
|
|
gptkbp:annualVisitors
|
15%
|
|
gptkbp:awards
|
Best Startup 2021
|
|
gptkbp:CEO
|
gptkb:John_Doe
|
|
gptkbp:clinicalTrials
|
gptkb:New_York
500
Phase 3
|
|
gptkbp:collaboratedWith
|
gptkb:University_of_California
|
|
gptkbp:communityEngagement
|
Local Schools
|
|
gptkbp:communityPartnerships
|
gptkb:GHI_Research_Labs
|
|
gptkbp:focusArea
|
Genetic Engineering
|
|
gptkbp:foundedIn
|
2000
|
|
gptkbp:founder
|
Jane_Smith
|
|
gptkbp:funding
|
10 million USD
|
|
gptkbp:headquarters
|
gptkb:San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
XYZ Biotech
|
|
gptkbp:innovation
|
Tech Innovator 2023
|
|
gptkbp:investmentFocus
|
Series B
Venture_Capital_Firm
|
|
gptkbp:market
|
200 million USD
2022
Global
|
|
gptkbp:numberOfEmployees
|
200
|
|
gptkbp:partnerships
|
gptkb:ABC_Pharmaceuticals
|
|
gptkbp:patentAbstract
|
2023
|
|
gptkbp:patentCitation
|
gptkb:CRISPR_Technology
|
|
gptkbp:products
|
Ongoing
Gene Therapy
|
|
gptkbp:regulatoryCompliance
|
FDA_Approved
|
|
gptkbp:research_areas
|
Rare Diseases
|
|
gptkbp:researchAreas
|
Cancer Treatment
|
|
gptkbp:researchInterest
|
Global Health Initiative
|
|
gptkbp:revenue
|
50 million USD
|
|
gptkbp:socialResponsibility
|
Health Education Programs
|
|
gptkbp:subsidiary
|
XYZ Diagnostics
|
|
gptkbp:sustainabilityInitiatives
|
Green Biotech Practices
|
|
gptkbp:technology
|
Biomanufacturing
|
|
gptkbp:trainingPrograms
|
Biotech Skills Training
|
|
gptkbp:website
|
www.xyzbiotech.com
|